These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32195732)

  • 1. Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy.
    Bewtra M; Lichtenstein GR
    Am J Gastroenterol; 2020 May; 115(5):687-688. PubMed ID: 32195732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.
    Monteleone G; Di Sabatino A; Ardizzone S; Pallone F; Usiskin K; Zhan X; Rossiter G; Neurath MF
    Aliment Pharmacol Ther; 2016 Mar; 43(6):717-24. PubMed ID: 26766141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.
    Monteleone G; Neurath MF; Ardizzone S; Di Sabatino A; Fantini MC; Castiglione F; Scribano ML; Armuzzi A; Caprioli F; Sturniolo GC; Rogai F; Vecchi M; Atreya R; Bossa F; Onali S; Fichera M; Corazza GR; Biancone L; Savarino V; Pica R; Orlando A; Pallone F
    N Engl J Med; 2015 Mar; 372(12):1104-13. PubMed ID: 25785968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study.
    Marafini I; Stolfi C; Troncone E; Lolli E; Onali S; Paoluzi OA; Fantini MC; Biancone L; Calabrese E; Di Grazia A; Monteleone I; Lenti MV; Di Sabatino A; Monteleone G
    BioDrugs; 2021 May; 35(3):325-336. PubMed ID: 33871807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
    Sands BE; Feagan BG; Sandborn WJ; Schreiber S; Peyrin-Biroulet L; Frédéric Colombel J; Rossiter G; Usiskin K; Ather S; Zhan X; D'Haens G
    Am J Gastroenterol; 2020 May; 115(5):738-745. PubMed ID: 31850931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.
    Feagan BG; Sands BE; Rossiter G; Li X; Usiskin K; Zhan X; Colombel JF
    Gastroenterology; 2018 Jan; 154(1):61-64.e6. PubMed ID: 28847751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment.
    Arrico L; Stolfi C; Marafini I; Monteleone G; Demartis S; Bellinvia S; Viti F; McNulty M; Cabani I; Falezza A; Di Bari L
    Nucleic Acid Ther; 2022 Aug; 32(4):312-320. PubMed ID: 35263186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate for induction of remission in refractory Crohn's disease.
    Alfadhli AA; McDonald JW; Feagan BG
    Cochrane Database Syst Rev; 2005 Jan; (1):CD003459. PubMed ID: 15674908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate for induction of remission in refractory Crohn's disease.
    Alfadhli AA; McDonald JW; Feagan BG
    Cochrane Database Syst Rev; 2003; (1):CD003459. PubMed ID: 12535475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
    Monteleone G; Stolfi C; Marafini I; Atreya R; Neurath MF
    Mol Diagn Ther; 2022 Sep; 26(5):477-481. PubMed ID: 35841457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: mongersen in Crohn's disease--a new contribution to the beginning of a long-awaited therapeutic revolution?
    Kirchgesner J; Sokol H
    Aliment Pharmacol Ther; 2016 Apr; 43(7):838-9. PubMed ID: 26932411
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?
    Danese S; Fiorino G; Peyrin-Biroulet L
    Gastroenterology; 2015 Oct; 149(4):1121-3. PubMed ID: 26319033
    [No Abstract]   [Full Text] [Related]  

  • 16. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Prefontaine E; Macdonald JK; Sutherland LR
    Cochrane Database Syst Rev; 2009 Oct; (4):CD000545. PubMed ID: 19821270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine for induction of remission in Crohn's disease.
    McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Prefontaine E; Macdonald JK; Sutherland LR
    Cochrane Database Syst Rev; 2010 Jun; (6):CD000545. PubMed ID: 20556747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Good results: antisense-oligonucleotide Mongersen is in Crohn's disease].
    Moskaleva M
    Dtsch Med Wochenschr; 2015 May; 140(10):710-1. PubMed ID: 26171473
    [No Abstract]   [Full Text] [Related]  

  • 20. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
    Kennedy BW
    N Engl J Med; 2015 Jun; 372(25):2461. PubMed ID: 26083214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.